Byrne et al. proved that empagliflozin, another SGLT2 inhibitor, can significantly worsen cardiac dysfunction by inhibiting nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome activation in an animal model of heart failure [13]. The gene discussed is SLC5A2; the disease is heart failure.